DBV Technologies (NASDAQ:DBVT) – Equities research analysts at Jefferies Group boosted their FY2021 earnings estimates for shares of DBV Technologies in a report issued on Wednesday, March 14th, Zacks Investment Research reports. Jefferies Group analyst E. Yang now anticipates that the company will earn $4.74 per share for the year, up from their previous estimate of $4.37. Jefferies Group also issued estimates for DBV Technologies’ FY2022 earnings at $8.84 EPS.
Several other equities research analysts have also commented on the company. ValuEngine upgraded DBV Technologies from a “strong sell” rating to a “sell” rating in a research note on Monday, April 2nd. Zacks Investment Research downgraded shares of DBV Technologies from a “buy” rating to a “hold” rating in a report on Monday, April 2nd. BidaskClub raised shares of DBV Technologies from a “strong sell” rating to a “sell” rating in a report on Thursday, March 29th. Deutsche Bank set a $33.00 target price on shares of DBV Technologies and gave the stock a “buy” rating in a report on Tuesday, March 27th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a report on Thursday, March 15th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. DBV Technologies currently has an average rating of “Hold” and a consensus price target of $46.00.
Shares of NASDAQ:DBVT traded down $0.11 during midday trading on Thursday, hitting $23.81. The company had a trading volume of 121,584 shares, compared to its average volume of 247,909. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.37 and a quick ratio of 4.37. The firm has a market capitalization of $1,358.03, a price-to-earnings ratio of -9.19 and a beta of 0.98. DBV Technologies has a 12-month low of $20.08 and a 12-month high of $50.57.
A number of institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its holdings in DBV Technologies by 10.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,797,789 shares of the company’s stock worth $118,738,000 after buying an additional 257,210 shares during the period. ArrowMark Colorado Holdings LLC boosted its holdings in shares of DBV Technologies by 94.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,007,684 shares of the company’s stock valued at $49,389,000 after purchasing an additional 977,491 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in shares of DBV Technologies by 3,604.2% during the 4th quarter. Perceptive Advisors LLC now owns 978,619 shares of the company’s stock valued at $24,075,000 after purchasing an additional 952,200 shares during the last quarter. Citadel Advisors LLC boosted its holdings in shares of DBV Technologies by 57.3% during the 4th quarter. Citadel Advisors LLC now owns 288,879 shares of the company’s stock valued at $7,106,000 after purchasing an additional 105,224 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of DBV Technologies by 21.3% during the 4th quarter. Jane Street Group LLC now owns 195,967 shares of the company’s stock valued at $4,924,000 after purchasing an additional 34,355 shares during the last quarter. 45.68% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/dbv-technologies-sa-to-post-fy2021-earnings-of-4-74-per-share-jefferies-group-forecasts-dbvt.html.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Get a free copy of the Zacks research report on DBV Technologies (DBVT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.